DexCom, Inc. (NASDAQ:DXCM) Holdings Boosted by Essex Financial Services Inc.

Essex Financial Services Inc. grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 3.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,617 shares of the medical device company’s stock after purchasing an additional 303 shares during the period. Essex Financial Services Inc.’s holdings in DexCom were worth $748,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Exchange Traded Concepts LLC lifted its stake in DexCom by 39.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 12,276 shares of the medical device company’s stock worth $823,000 after acquiring an additional 3,474 shares in the last quarter. Creative Planning increased its holdings in shares of DexCom by 22.3% in the 3rd quarter. Creative Planning now owns 59,573 shares of the medical device company’s stock valued at $3,994,000 after purchasing an additional 10,880 shares during the period. Swedbank AB lifted its position in shares of DexCom by 15.2% in the third quarter. Swedbank AB now owns 213,864 shares of the medical device company’s stock worth $14,337,000 after purchasing an additional 28,289 shares in the last quarter. Vontobel Holding Ltd. boosted its holdings in shares of DexCom by 92.0% during the third quarter. Vontobel Holding Ltd. now owns 70,586 shares of the medical device company’s stock worth $4,732,000 after purchasing an additional 33,820 shares during the period. Finally, Orin Green Financial LLC grew its position in DexCom by 36.8% during the third quarter. Orin Green Financial LLC now owns 6,540 shares of the medical device company’s stock valued at $438,000 after purchasing an additional 1,759 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In related news, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares of the company’s stock, valued at $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of the stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,342 shares of company stock worth $3,628,069 over the last three months. Company insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on DXCM shares. Raymond James decreased their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Royal Bank of Canada reduced their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Finally, Citigroup raised their target price on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $98.41.

DexCom Stock Performance

NASDAQ:DXCM opened at $83.87 on Thursday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The firm’s 50-day moving average is $82.05 and its 200-day moving average is $75.13. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a market cap of $32.76 billion, a price-to-earnings ratio of 50.22, a PEG ratio of 2.26 and a beta of 1.14.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.